$BG

Bunge Global (NYSE:BG) Beats Q2 CY2026 Sales Expectations

Bunge Global (NYSE:BG) reported Q2 CY2026 results, with sales rising 88.3% year on year to $24.04 billion, topping Wall Street’s revenue estimate by 9.3%, according to the company. Non-GAAP profit was $2 per share, 2.9% above consensus. The article also cites Q2 cash burn of $1.03 billion and notes the stock was about $117.50 after results.

Original reporting
Published Jul 29, 2026, 11:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 12:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bunge Global (NYSE:BG) Beats Q2 CY2026 Sales Expectations — source image
Decision brief

The 30-second read

$BGBullishMed
01

Why it matters

The article discloses a specific Q2 CY2026 revenue and EPS beat versus Wall Street expectations, plus a forward expectation of revenue decline and a cash burn figure, shaping a mixed near-term versus medium-term trading view.

02

Market read

Traders can reassess near-term earnings momentum from the beat, while monitoring whether the projected revenue deceleration and cash burn undermine the quality of the earnings.

03

What to watch

Free cash flow is described as cash burn ($1.03B in Q2) and only slowing from last year, which could matter for valuation and capital-return expectations even with EPS outperformance.

Relevance 7/10Novelty 7/10Timing: after-hours/just after Q2 results release (stock noted flat at $117.50 immediately following)

Background

Bunge is an agribusiness and food company processing oilseeds and grains into oils, protein meals, flours, and specialty ingredients, operating across both hemispheres.

Company-level read

Ticker impact

$BGBullishMedium confidence
Context

Bunge reported Q2 CY2026 sales up 88.3% to $24.04B and non-GAAP EPS of $2, beating revenue and consensus estimates.

Expected impact

Near-term bias positive on the beat, but upside may be capped if investors focus on the projected 3.1% revenue decline.

Evidence & confidence

The text provides concrete earnings datapoints (sales, EPS, beat vs consensus) plus a forward-looking revenue deceleration expectation, which can temper post-earnings enthusiasm.

Market effects

Signals resilience in agribusiness/food processing demand despite geopolitical and trade-flow uncertainty, which can influence sentiment across staples and commodity-linked processors.

No specific regional demand or policy changes are cited beyond general geopolitical uncertainty.

Geopolitical uncertainty and shifting trade flows are referenced, implying broader volatility in global agri trade that can affect margins and volumes.

Counterpoint

The article’s forward-looking note of expected revenue decline (-3.1% over 12 months) suggests the beat may be partly cyclical or transitory rather than a durable inflection.

Key entities

  • Bunge Global

    Reported Q2 CY2026 sales and non-GAAP profit, with revenue up 88.3% YoY and EPS of $2, beating consensus; also reported significant cash burn.

Related articles

$BGMed

Why is Bunge stock rallying today?

Investing.com reports Bunge shares rose about 3.7% after its Q2 2026 results (released July 29). Adjusted EPS was $2.00 vs ~$1.95 expected, and revenue was $24.04B vs expectations. The stock had fallen on concerns about Viterra integration and working capital. Analysts at Texas Capital and BMO reiterated Buy, with a $150 target, and an Aug. 18 ex-dividend date for a $0.72 quarterly payment.

$BGMedAI 8/10

PTSB acquisition: Shareholders approve transaction

Permanent TSB (PTSB) shareholders approved BAWAG Group’s all-cash offer to buy 100% of PTSB’s issued share capital. The scheme meeting vote backed the transaction with 91% of votes cast, and related resolutions at the EGM received required approvals. Completion is expected in Q4 2026 or Q1 2027, pending court sanction and remaining regulatory approvals.

$BGMedAI 8/10

Bunge Global Raises 2026 Adj. EPS Outlook Range

Bunge Global SA (BG) raised its 2026 adjusted EPS outlook to $9.25 to $9.75 from $9.00 to $9.50, citing higher Soybean Processing and Refining and Softseed Processing and Refining, and lower Grain Merchandising and Milling. Q2 earnings were $678 million, or $3.47/share, versus $354 million, or $2.61/share a year earlier. Revenue rose 88.3% to $24.041 billion. Shares were up 1.29% pre-market at $118.88.

$BGMedAI 8/10

Bunge beats second-quarter profit estimates on strong processing margins By Reuters

Reuters reports Bunge beat Wall Street’s Q2 profit estimates, citing strong soybean and softseed processing margins. The company raised its 2026 adjusted earnings forecast to $9.25 to $9.75 per share. Soybean processing and refining net sales were $12.07 billion, and softseed net sales were $4.09 billion. Reuters links improved demand to higher U.S. corn and soybean prices.

$BGMed

Bunge Global SA (BG): Results of Operations and Financial Condition

Bunge Global SA (BG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 epr06302026.htm EX-99.1 Document Bunge Reports Second Quarter 2026 Results St. Louis, MO - July 29, 2026 - Bunge Global SA (NYSE: BG) today reported second quarter 2026 results • Q2 GAAP diluted EPS of $3.47 vs. $2.61 in the prior year; $2.00 vs. $1.31 on an adjusted ba

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.